Bio-Techne Yönetim
Yönetim kriter kontrolleri 2/4
Bio-Techne CEO'su Kim Kelderman, Feb2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 6.85M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.1% maaş ve 88.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.025% ine doğrudan sahiptir ve bu hisseler $ 2.78M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 7.8 yıldır.
Anahtar bilgiler
Kim Kelderman
İcra Kurulu Başkanı
US$6.9m
Toplam tazminat
| CEO maaş yüzdesi | 11.1% |
| CEO görev süresi | less than a year |
| CEO sahipliği | 0.02% |
| Yönetim ortalama görev süresi | 1.3yrs |
| Yönetim Kurulu ortalama görev süresi | 7.8yrs |
Son yönetim güncellemeleri
Recent updates
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$151m |
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$2m | US$73k | US$126m |
Tazminat ve Piyasa: Kim 'nin toplam tazminatı ($USD 6.85M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.66M ).
Tazminat ve Kazançlar: Kim şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.
CEO
Kim Kelderman (57 yo)
less than a year
Görev süresi
US$6,852,495
Tazminat
Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.85m | 0.025% $ 2.8m | |
| Executive VP of Finance & CFO | 10.6yrs | US$5.20m | 0.067% $ 7.6m | |
| Senior VP | 1.7yrs | US$1.46m | 0.0011% $ 120.1k | |
| President of Protein Sciences Segment | 2.8yrs | US$3.65m | 0.0070% $ 789.4k | |
| President of Diagnostics & Genomics | less than a year | US$2.27m | Veri yok | |
| VP & CTO | less than a year | Veri yok | Veri yok | |
| Senior Director of Investor Relations & Corporate Development | no data | Veri yok | Veri yok | |
| Vice President of Sales and Marketing | no data | Veri yok | Veri yok | |
| Senior Vice President of Strategy & Corporate Development | less than a year | Veri yok | Veri yok | |
| Senior VP & Chief Human Resources Officer | less than a year | Veri yok | Veri yok | |
| Managing Director | 8.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Analytical Solutions Division | 1.8yrs | Veri yok | Veri yok |
1.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: TECH 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$6.85m | 0.025% $ 2.8m | |
| Independent Chairman of the Board | 21.8yrs | US$410.46k | 0.028% $ 3.2m | |
| Independent Director | 15.5yrs | US$300.46k | 0.030% $ 3.4m | |
| Independent Director | 7.8yrs | US$275.46k | 0.0087% $ 981.9k | |
| Independent Director | 14.5yrs | US$290.46k | 0.028% $ 3.2m | |
| Independent Director | 4.3yrs | US$291.50k | 0.0045% $ 508.5k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.4yrs | US$275.46k | 0.0059% $ 666.0k | |
| Independent Director | 7.8yrs | US$275.46k | 0.0087% $ 981.9k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | less than a year | US$113.73k | 0.0014% $ 152.9k |
7.8yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: TECH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).